Aurobindo Pharma plans to expand its footprints in EU countries

03 Jul 2017 Evaluate

Aurobindo Pharma is planning to expand into European Union (EU) countries such as Poland and the Czech Republic as part of its broader efforts to consolidate business over the next 3-4 years. The company, which is also eyeing growth in Italy and Spain, is planning to launch various new products in the US market.

Moreover, the Hyderabad-based firm is working on plans to launch cancer treatment and injectable products in the European Union. The acquisition of Generis Farmaceutica SA has already catapulted the company into a big league in the Portuguese generic market in terms of value and volume. It has also completed the acquisition of Orocal brand to leverage its position as a key player in the French drug market.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1131.80 28.25 (2.56%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.